CARCINOEMBRYONIC ANTIGEN (CEA) (Gold & Freedman, 1965) remains one of the most useful tumour-associated substances to monitor malignant disease. Unfortunately, its assay in the blood provides only a crude guide to tumour behaviour; there are two main reasons for this. First, CEA is a heterogeneous large glycoprotein which is difficult to define in precise chemical and immunological terms with many of the available reagents. Second, regulation of CEA levels in cancer patients is subject to numerous poorly understood biological variables with respect to its production and release by tumours, and the mode by which the host metabolizes and clears it from the circulation.
Of fundamental importance to the clinical application of anv marker is its ability to provide a reliable index of tumour mass. Unfortunately, CEA may have certain failings in this respect. It is true that there is usually an increase in CEA in individual patients as disease advances (Steward et al., 1974; Di Saia ct al., 1975; Khoo & Mackay, 1976; Cove et al., 1979; Dent & McCullough, 1980 and that many patients with advanced malignancies are likely to have high levels of CEA (Chu & Nemoto, 1973; Steward et al., 1974; Barrelet & Mach, 1975; Vincent et al., 1975; Khoo & Mackay, 1976; Di Saia et al., 1977; Borthwick et al., 1977; Martin et al., 1977; Waalkes et al., 1980; Wanebo 1980 ) which may correlate with the stage of the disease (Martin et al., 1977; Cove et al., 1979; Khoo et al., 1979; Khoo & Mackay ,1976; Gropp et al., 1980; Joyce et al., 1980) HK1, 6, 7, 9) , one breast (S32) and one lung (p246) were selected for use. The number of previous passages ranged from 7 to 16. Plasma CEA levels ranged from 40 to 306 ng/ ml. The histological characteristics of the primary tumours were retained in the xenografts, except that stroma was much reduced and predominantly of mouse origin, as is well described by Warenius (1979) . The karyotypes were in all cases human; only occasional murine chromosomes being encountered. There was a considerable range of modal number, from 40 to 80 chromosomes.
Immune-deprived inice.-CBA/LAC mice were used throughout. Preparation involved thymectomy at 4-6 weeks of age, and 3 weeks later, whole-body irradiation (9 Gy at 60 cGy/min; 200 kV X-ray machine) followed by reconstitution within 2 h by an i.v. injection of 5 x 106 syngeneic marrow cells (Miller et al., 1963 (Nowak et al., 1978 Collection of blood samples.-Individual blood samples were usually collected by venesection via the infra-orbital sinus. When mice were to be killed cardiac puncture was used. Fine glass pipettes coated with 360 ,ug tripotassium EDTA were used and -200 a1l withdrawn each time. Plasma was separated and stored at -70°C until assayed.
CEA assay.-For a number of reasons it was necessary to devise a radioimmunoassay especially for this study. Only small volumes of blood could be removed from mice without risk of serious hypovolaemia. The automated assay in clinical use required large plasma samples. Since with the available equipment, samples of 50 1A were found to be the minimum before unacceptable errors from the manual pipetting manoeuvres occurred, most of the mouse sample would be required for a single assay. It was thus necessary to devise a more sensitive assay.
Chemical precipitation for separating the antisera-bound from free CEA was chosen, because it is simpler and cheaper than a double-antibody method, and because mouse anti-CEA/CEA complexes are unlikely to reduce the amount of antigen available for binding in this type of assay (Stevens et al., 1978) .
The assay was set up in the conventional way by Dr M. G. Ormerod and Miss N. Neylon. The CEA used was isolated from hepatic metastases of a human colonic carcinoma and purified to satisfy criteria described by Westwood & Thomas (1975) and Westwood et al. (1978) . Anti-CEA sera were raised in a rabbit by the method described by . CEA was labelled with 1251 using chloramine T by Mr M. Capp. All dilutions were in phosphate-buffered saline (0-05M phosphate, 0-15M NaCl, pH 7415) Fig. 2 .
The precision throughout the dose range is determined from these 95% tolerance limits by taking half this difference divided by the nominal dose to give the relative dose error at this point. These dose errors, plotted against dose to determine the region of minimum error in the assay calibration curve revealed a minimum dose error of 12.5% at 60 ng/ml.
At the extreme ranges of the assay this was 68 and 78%.
Reproducibility.-Because batches of completed experiments were assayed together on the same assay day, and because the relative rather than absolute values of the CEA estimations were important, the inter-assay variation was irrelevant. Samples of known value were included in each assay and intraassay variability was -10%.
Tissue CEA.-CEA was extracted from freshly resected specimens using perchloric acid by the method of Khoo et al. (1973) . CEA levels were measured by the doubleantibody radioimmunoassay method of Laurence et at. (1972) which is used for measuring plasma levels in hospital patients at the Ludwig Institute. Although there were obvious variations in precision at individual CEA titres between this assay and the mouse plasma assay described above, there were no discernible qualitative differences.
Statistics.-The significance of the analysis of data was calculated using Spearman's test of rank correlation coefficient.
RESULTS
CEA blood levels related to tumour mass CEA rarely became detectable in the blood of mice bearing the human tumours until the total tumour volume reached -06 ml. As individual tumours reached Fig. 3 . The wide scatter of CEA values within each tumour group was of particular interest, and in only half was there a correlation with tumour volume HKI (Fig. 3 ) (P<O001), HK7 (P<0-05) and 832 (P<0 05).
The greatest discrepancies were found in HK6, where the largest tumours were associated with the lowest plasma CEA levels, whereas in p246 and HK9, mice with relatively small tumour loads occasionally had high levels of circulating CEA. Among HK6, HK9 and p246, it appeared that the highest CEA levels occurred in mice bearing tumour burdens in the mid range. It was considered that some discrepancies might have occurred because of centrilobular necrosis in the larger ttimours. However, although post- mortem examination confirmed this in certain cases, low CEA levels were found in association with some large tumours in which centrilobular necrosis was not excessive. The multiple implant study was designed to minimize the effect of centrilobular necrosis. A much wider range (0 5-8g) could thus also be attained. The results again revealed a wide variation, but an overall linear correlation (P < 0.05) (Fig. 4) . One notable discrepancy was in a mouse carrying one of the largest tumour loads, which had a particularly low plasma level of CEA. The relationship of tumour CEA content, tumour mass and CEA blood levels HK9 and HK6 tumours were used for this investigation. The HK9 study was an extension of the multiple-implant investigation described above, whereas the HK6 multiple implants were set up specially. (The plasma CEA estimations for this particular group were rendered invalid through technical fault.) Whereas HK6 demonstrated a clear linear correlation (P < 0.05) of tumour CEA content with tumour mass, considerable disparity existed in HK9 (Fig. 5) indicating that CEA concentration in xenograft tumours does not remain constant. The relationship of tumour CEA content to plasma levels in HK9 was even more disparate. The possibility had to be considered that where there was wide discrepancy between tumour mass and CEA blood levels, there may have been a corresponding discrepancy in tumour CEA content, but this was clearly not the case.
There is no indication, therefore, that tumours with low or high concentrations were especially associated with corresponding plasma CEA levels.
DISCUSSION
Previous xenograft investigators have pointed out that tumours must reach a certain size before CEA becomes detectable in the blood (Primus et al., 1973; Mach et al., 1974; Sordat et al., 1974; Miwa et al., 1976; Lewis & Keep, 1981) . Indeed, CEA was as rare in mice bearing small tumours in the present study that it became policy not to measure plasma levels until the total tumour bulk was 1'5 ml. Such a size represents 5 5% of the total weight of the tumour-bearing host, which in comparison to malignancies in patients is enormous. In contrast, relatively small tumours in patients are capable of producing very high levels of circulating CEA. This curious observation has also been made for other markers, such as human chorionic gonadotrophin (hCG) (Kameya et al., 1975 ) and x-foetoprotein (AFP) (Raghavan et al., 1980) produced by xenograft tumours. The reason cannot be wholly explained by assay insensitivity, since small concentrations should be detectable in spite of measurement being inaccurate. It would seem logical that CEA would only become detectable when the amount produced and released by the tumour exceeds that eventually metabolized. However, although it has been shown that CEA is rapidly cleared by the liver in mice (Thomas et al., 1976; Thomas & Hems, 1975 ) the possibility of a threshold level for CEA clearance has not yet been specifically investigated.
The possibility that there may be a change in CEA synthesis during growth should seriously be considered. Certainly, as tumours grow centrilobular necrosis sets in, and the CEA concentration is naturally smaller when this becomes extensive . It is not surprising that Lewis & Keep (1981) should find in their single tumour line that CEA concentrations vary widely, because their series produced tumours of vastly differing size. The linear correlation which was found in the HK6 tumours in the present investigation may be because the tumours were harvested early, before serious centrilobular necrosis could have occurred. The possibility that necrosis may be an important factor affecting CEA blood levels has been investigated by the author in a separate study (Quavle, 1982) in which it was found that when necrosis occurred rapidly and extensively, considerable increases in CEA titres were frequent. Nevertheless, the fact that the tumour mass vs tumour CEA correlation did not exist in HK9, in spite of similar conditions, indicates that factors other than necrosis are responsible.
A further anomaly identified in this study is the finding that tumour size does not always correlate with plasma CEA. Again this cannot wholly be explained on the basis of tumour necrosis because, if it were, the correlation in the multipleimplant study, which was harvested early, should have been closer than in volume studies.
Until recently, Miwa et al. (1976) were the only workers to investigate the relationship between blood CEA and tumour xenograft size. Their claim for a direct correlation does not, however, stand up to close scrutiny, mainly because the number of samples is small (5) and the spread of levels and tumour size uneven. Stragand et al. (1980) and Lewis & Keep (1981) failed to demonstrate any correlation in their more recent detailed studies on a single tumour line, but the validity of their observation should perhaps be viewed with some circumspection since they were using tumours which, in some cases, were as laige as 8-8 and 7-14 g respectively, which would be expected to contain a considerable degree of central necrosis. Indeed Lewis & Keep (1981) specifically stated that "central necrosis was a consistent feature" in their tumour line. Since the present sudy has indicated behavioural differences between tumour lines, it is conceivable that the two tumour lines used by these authors may not be representative. A further factor, again acknowledged by Lewis & Keep (1981) , was that their assay for CEA by a double antibody technique may have been incapable of determining the presence of CEA molecules masked by murine immunoglobulins.
The variable ability of CEA to reflect tumour burden is not wholly unexpected, since a review of the extensive literature indicates that levels of CEA in the blood are affected by numerous other biological variables. Even so, because the validity of xenograft tumour models for such investigations remains in doubt, this failing of CEA may have been exaggerated.
